Rexahn Pharmaceuticals
As of the edition of 20 October 2026, Rexahn Pharmaceuticals runs 2 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Rexahn Pharmaceuticals was merged in 2020; successor Ocuphire Pharma, Inc..
- Rexahn Pharmaceuticals, Inc.: merged in 2020; successor Ocuphire Pharma, Inc.
Drugs by status
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| AKT1 RAC-alpha serine/threonine-protein kinase | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Rexahn Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 3 trials led
- Digestive system: 1 trials led
- Hormones: 1 trials led